Clarification sought from Sun Pharmaceutical Industries Ltd
The Exchange has sought clarification from Sun Pharmaceutical Industries Ltd with respect to news article appearing in Business Line on December 29, 2016 titled "Blast at sun pharma unit."The reply is awaited. Sun Pharma: It is down but not out
Product acquisition gains partly offset losses because of pricing collusion probe in the US Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Sudhir V Valia Sun Pharma Arm Picks Up 14.6% Stake In US Company For $13 Million
scPharmaceuticals Inc is a United States-based pharmaceutical company developing a portfolio of transformative pharmaceutical products for subcutaneous delivery. Updates
Sun Pharmaceutical Industries Ltd has informed BSE that one of the wholly owned subsidiaries of the Company has acquired13,000,000 Series B Preferred Stock of scPharmaceuticals Inc. (equivalent to 14.58% fully diluted equity stake on conversion) by way of allotment. scPharmaceuticals Inc., is a United States pharmaceutical company developing a portfolio of transformative pharmaceutical products for subcutaneous delivery. Cancer treatment: Sun Pharma to acquire Novartis' cancer drug Odomzo for $175 million
Odomzo, approved by the US FDA in July 2015, has marketing approval in over 30 countries. Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Raksha S Valia Sun Pharma to acquire branded oncology product Odomzo (sonidegib) for global markets
Sun Pharmaceutical Industries Ltd has informed BSE regarding a Press Release dated December 22, 2016, titled "Sun Pharma to acquire branded oncology product Odomzo (sonidegib) for global markets". Updates
Sun Pharmaceutical Industries Ltd has informed BSE regarding Update on acquisition of 85.1% of JSC Biosintez, a Russian Pharmaceutical Company. Sun Pharma unit asks US FDA to withdraw nod for 28 drug applications of Ranbaxy
In a BSE filing, Sun Pharmaceutical Industries said: One of the company's wholly-owned subsidiaries has voluntarily requested the USFDA to withdraw approval for 28 Abbreviated New Drug Applications (ANDAs).